-
HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial
Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27% Median progression-free survival was 11.7 months… Source: Read More
-
FDA Grants Accelerated Approval to Tudriqev for Advanced Melanoma Treatment
NASDAQ: $REPL A New Frontier in Melanoma Therapy The FDA has officially granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a significant development for patients battling unresectable or metastatic melanoma. This new treatment is designed to be used in combination with nivolumab, providing a novel therapeutic option for those facing this aggressive form of skin cancer.…